Einfluss der Schilddrüsenfunktion auf das Körpergewicht

Zusammenfassung

Sehr viele Übergewichtige sind der Meinung, dass ihre Gewichtsveränderungen ursächlich auf Störungen der Schilddrüsenfunktion zurückzuführen sind.

De facto sind aber die Einflüsse von Schilddrüsenfunktionsstörungen auf das Gewicht weitgehend ungeklärt.

Deshalb sollen die Zusammenhänge verlässlich über eine systematische Literatursuche und Bewertung geklärt werden.

Nach systematischen Übersichtsarbeiten wurden die Cochrane Library, NHSCRD (Centre for Reviews and Dissemination, York), Medline und Clinical Evidence durchsucht, aktuelle evidenzbasierte Leitlinien sind erfasst (GIN.net). Nach randomisierten kontrollierten Studien (RCTs) wurde in PubMED, EMBASE und CENTRAL der Cochrane Library gesucht. Die Methodik orientiert sich an den Cochrane-Gruppen.

Die klinisch manifeste Schilddrüsenunterfunktion führt zu einer Gewichtszunahme. Sie wird mit dem Empfehlungsgrad A mit Levothyroxin behandelt. Wissenschaftlich gibt es dazu keine Alternative, weitere Studien wären unethisch. Die Hyperthyreose führt zur Gewichtsabnahme.

Zur subklinischen Hypothyreose und zur subklinischen Hyperthyreose finden sich weltweit nicht ausreichend verlässliche Studien um sicher auszusagen, dass ein Einfluss auf das Gewicht gegeben ist. Viel bleibt Spekulation, viele Menschen werden überbehandelt.

Abstract

Many patents with weight problems believe they are caused by thyroidal dysfunction. In contrast, the influences of thyroidal dysfunction on body weight are not well documented.

Therefore this work was done to evaluate systematically the possible connection of weight changes and thyroid function.

The following databases were used to identify systematic reviews: Medline to November 2014, Embase and The Cochrane Database of Systematic Reviews. Additional searches were carried out in the Database of Abstracts of Reviews of Effects (DARE) and the Health Technology Assessment (HTA) Database and in GIN.net for guidelines. We also searched Medline, Embase, and CENTRAL (Cochrane Library) for RCTs. We used the search strategy of the Cochrane Collaboration.

Clinical (overt) hypothyroidism leads to weight gain. Levothyroxine is beneficial in clinical hypothyroidism (GRADE A recommendation) and the treatment of choice.

A placebo-controlled trial would be considered unethical.

Clinical hyperthyroidism causes weight loss.

Our search does not yield enough RCTs to evaluate possible influences of subclinical hypothyroidism/hyperthyroidism on bodyweight. Many recommendations are not evidence based and this may lead to overtreatment.

Schlüsselwörter

Gewicht - Adipositas - Hyperthyreose - Hypothyreose - Autoimmunthyreoiditis - systematische Übersicht

Keywords

body weight - obesity - hyperthyroidism - hypothyroidism - Hashimoto's thyroiditis - systematic review

• Literatur

• 1 McKibbon KA, Fridsma DB. Effectiveness of clinician-selected electronic information resources for answering primary care physicians’ information needs. J Am Med Inform Assoc 2006; 13: 653-659
• 2 Börner U. „Aktion Durchblick“ – Der Effekt von Evidenz basierten Patienteninformationen (EBPI) zur Vermeidung von Fehl- und Überbehandlung in einer großen Zuweisungspraxis. Beitrag für den Berliner Gesundheitspreis 2013 „KnHow? – Wie kommt Wissen in die Praxis?“
• 3 Allahabadia A, Razvi S, Abraham P et al. Diagnosis and treatment of primary hypothyroidism. BMJ 2009; 338: b725
• 4 Villar HCCE, Saconato H, Valente O et al. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database of Systematic Reviews 2007; (03) Art. No.: CD003419
• 5 Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C et al. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database of Systematic Reviews 2012; (10) Art. No.: CD009009
• 6 Si S, Moss JR, Sullivan TR et al. Effectiveness of general practice-based health checks: a systematic review and meta-analysis. Br J Gen Pract 2014; 64: e47-e53
• 7 Choosing Wisely. http://www.choosingwisely.org
• 8 Edwards AGK, Naik G, Ahmed H et al. Personalised risk communication for informed decision making about taking screening tests. Cochrane Database of Systematic Reviews 2013; (02) Art. No.: CD001865
• 9 Wiedemann R, Strehler E, Wiedemann P. Krankmacher Lebensstil. conkom Verlag; 2005. ISBN: 3-00-017436-2
• 10 Guyatt G, Oxman AD, Vist G et al., for the GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926
• 11 van Zuuren EJ, Albusta AY, Fedorowicz Z et al. Selenium supplementation for Hashimoto's thyroiditis. Cochrane Database of Systematic Reviews 2013; (06) Art. No.: CD010223
• 12 Abraham P, Avenell A, McGeoch SC et al. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database of Systematic Reviews 2010; (01) Art. No.: CD003420
• 13 NICE guidelines [PH53]. Overweight and obese adults – lifestyle weight management: guidance 27 May 2014. NICE:
• 14 Interdisziplinäre Leitlinie der Qualität S3 zur „Prävention und Therapie der Adipositas“. © DAG e.V.; 2014
• 15 Wilson GR. Hypothyroidism. John Wiley & Sons, Inc.; 07/2014. http://www.essentialevidenceplus.com/content/eee/149
• 16 Clinical Evidence. BMJ Publishing Group Limited; 2014. clinicalevidence.bmj.com
• 17 Park P, Braunstein GD. Hyperthyroidism. John Wiley & Sons, Inc.; 04/2014. https://www.essentialevidenceplus.com/content/eee/139
• 18 Fox CS, Pencina MJ, D'Agostino RB et al. Relations of Thyroid Function to Body Weight: Cross-sectional and Longitudinal Observations in a Community-Based Sample. Arch Intern Med 2008; 168: 587-592
• 19 Nymes A et al. Serum TSH is positively associated with BMI. Int J Obes (Lond) 2006; 30: 100-105
• 20 Longhi S, Radetti G. Thyroid Function and Obesity. J Clin Res Pediatr Endocrinol 2013; 5 (Suppl. 01) 40-44
• 21 Monzani A, Prodam F, Rapa A et al. Natural history of subclinical hypothyroidism in children and adolescents and potential effects of replacement therapy: a review. Eur J Endocrinol 2012; Sep 18. [Epub ahead of print]
• 22 Boelaert K, Newby PR, Simmonds MJ et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 2010; 123: 183.e1-9
• 23 Reid SM, Middleton P, Cossich MC et al. Interventions for clinical and subclinical hypothyroidism pre-pregnancy and during pregnancy. Cochrane Database of Systematic Reviews 2013; (05) Art. No.: CD007752 DOI: 10.1002/14651858.CD007752.pub3.
• 24 Rayman MP. Selenium and human health. The Lancet 2012; 379: 1256-1268
• 25 Jonklaas J, Nsouli-Maktabi H. Weight Changes in Euthyroid Patients Undergoing Thyroidectomy. Thyroid 2011; 21: 1343-1351
• 26 Jonklaas J, Bianco AC, Bauer AJ et al. Guidelines for the Treatment of Hypothyoidism. Thyroid 2014; September [Epub ahead of print]
• 27 Somwaru LL, Rariy CM, Arnold AM et al. The Natural History of Subclinical Hypothyroidism in the Elderly: The Cardiovascular Health Study. J Clin Endocrinol Metab 2012; 97: 1962-1969
• 28 Ochs N, Auer R, Bauer DC et al. Meta-analysis: Subclinical Thyroid Dysfunction and the Risk for Coronary Heart Disease and Mortality. Ann Intern Med 2008; 148: 832-845
• 29 Selmer C, Olesen JB, Hansen ML et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 2012; 345: e7895
• 30 Turner MR, Camacho X, Fischer HD et al. Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ 2011; 342: d2238
• 31 Rosario PW, Calsolari MR. How Selective Are the New Guidelines for Treatment of Subclinical Hypothyroidism for Patients with Thyrotropin Levels At or Below 10 mIU/L?. Thyroid 2013; 562-565
• 32 Bijay Vaidya B, Pearce SHS. Management of hypothyroidism in adults. BMJ 2008; 337: a801
• 33 Lenzer J. Unnecessary care: are doctors in denial and is profit driven healthcare to blame?. BMJ 2012; 345: e6230
• 34 Rugge JB, Bougatsos C, Chou R. Screening and Treatment of Thyroid Dysfunction: An Evidence Review for the U. S. Preventive Services Task Force. Ann Intern Med 2014; Oct 28. DOI: 10.7326/M14-1456.